• A2AR and A2BR heterodimers diminish ligand affinity for A2AR.• Endosomal GPCR signaling.• ENT1 driven Ado entry to immune cells.• Spliced variants of A2AR in tumor cells worsen the disease. This evidence concerns the gene SLC29A1 and neoplasm.